Okay. Sir, congratulations on a great set of numbers. Sir, I have one question about the current situation in West Asia. So, because of this, have you seen any setbacks in the last quarter?
Right, sir. So, thanks for clarification. But let's say, if this situation, if the war wasn't there, then you would have reported better numbers?
Sir, what is the expected timeline and ramp -up curve, and the cost advantages you have from the Indonesian plant?
Sir, I was actually trying to understand how it will impact our EBITDA per ton margins over the next 12 months?
Thank you so much for the opportunity and elaborate walkthrough of the products. My first question is how much of the 1336 crore order book, which we have will convert into FY2027 revenue and by when will it happen in FY2027?
Okay, so most likely we will recognize the entire order book into revenue.
Sir thank you so much for the opportunity. And first of all, I would like to congratulate the entire Zen team, because, we are talking about that we are playing a very significant role in the nation's defense system. So that is amazing to be associated with such a great company. Sir I have a question on UTS, which is, you mentioned that primarily the anti -drone system developed by U TS was provided to the DRDO. So when did we acquire U TS? And how much is it contributing to the turnover of Zen?
This is around the contribution.
Good morning, everybody. Thank you so much for the opportunity. My first question is about the comment about the two soft quarters. So, can we expect complete normalcy to return to the revenue recognition after two quarters? That is my first question.
So, when would we know about the visibility on the approvals?
Hello, sir. Thank you so much for the opportunity. Sir, I have one question I have is about the commentary you mentioned that the revenues will pick up from the second half of the year. And also you mentioned about Q4, there'll be a lot of pickups by the customers. So, can you please elaborate. I am new to the company.
Hello, sir. Thank you so much for the opportunity and congratulations on a great set of numbers. Sir, if you can elaborate a little bit on the joint venture with Krka Pharma. Can you please elaborate what are we doing because I am not tracking, I am recently tracking this company?
Right, sir. Thank you, and the second question is on cell and gene update, gene therapy. If you can highlight or elaborate what kind of revenues will kick in and what are we trying to achieve for a layman who understands a little bit about pharma, it will be helpful. Thank you.
Hello, sir. Thank you so much for the opportunity and congratulations on a great set of numbers. Sir, if you can elaborate a little bit on the joint venture with Krka Pharma. Can you please elaborate what are we doing because I am not tracking, I am recently tracking this company?
Right, sir. Thank you, and the second question is on cell and gene update, gene therapy. If you can highlight or elaborate what kind of revenues will kick in and what are we trying to achieve for a layman who understands a little bit about pharma, it will be helpful. Thank you.
Sir, thank you so much. Your commentary has always been very transparent. And I'm tracking this company for the first time. So, I wanted to ask, when you said that one molecule has been commercialized in FY25, and yet FY25 has been a muted year for us, so when another molecule will be commercialized in FY26, how much impact will it have on growth? Can you just share a comparison?
Right. And likely this molecule will be commercialized in the first quarter or second quarter?
Hello, sir. Good evening.
Thank you so much for the elaborate explanation on the performance of GAIL. I have one question. You have mentioned that there is an impact which is going to be squared off by the fourth quarter. Is that for the entire 900 crores which you mentioned, or it is for a partial amount? I mean, if you can elaborate, explain that.